HSP90AA1

Heat shock protein HSP 90-alpha · P07900 · HSP90AA1 on Sugi Atlas →

404,614 patent compounds predicted against HSP90AA1, 253,995 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Herbimycin (SCHEMBL32882)	0.86	17/20
Geldanamycin (SCHEMBL4154)	0.80	17/20
Geldanamycin (SCHEMBL4155)	0.80	17/20
Alvespimycin (SCHEMBL28195)	0.84	16/20
Primaquine (SCHEMBL22207)	0.76	10/20
Primaquine (SCHEMBL22208)	0.76	10/20
Primaquine (SCHEMBL41096)	0.68	8/20
Primaquine (SCHEMBL41097)	0.68	8/20
Chloroxine (SCHEMBL3350)	1.00	7/20
Iodoquinol (SCHEMBL3460)	1.00	6/20
Clioquinol (SCHEMBL3967)	1.00	5/20
Novobiocin (SCHEMBL24805)	1.00	5/20
Diethyltoluamide (SCHEMBL29976)	0.53	5/20
Esorubicin (SCHEMBL3864)	0.81	4/20
SCHEMBL18713	0.65	4/20
SCHEMBL42947	0.50	4/20
Rodorubicin (SCHEMBL8693)	0.47	4/20
SCHEMBL24065	0.42	4/20
SCHEMBL7876	0.39	4/20
Epirubicin (SCHEMBL3165)	1.00	3/20

Clinical trials — most relevant to HSP90AA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease	PHASE2	COMPLETED
OGX-427 in Castration Resistant Prostate Cancer Patients	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	COMPLETED
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)	PHASE1/PHASE2	COMPLETED
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer	PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.	PHASE2	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma	PHASE1	COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies	PHASE1	WITHDRAWN
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
STA-9090 in Patients With Advanced Hepatocellular Cancer	PHASE1	COMPLETED
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis	nan	COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk	nan	COMPLETED
Chronic Heat Therapy for Improving Vascular Health	nan	COMPLETED
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer	nan	UNKNOWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Acute Passive Heating in Healthy Older Adults	nan	COMPLETED
Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer	nan	UNKNOWN
Cardioprotective Benefit of Passive Heat Therapy in Higher-Level Spinal Cord Injury: Safety and Proof of Concept	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HSP90AA1 binder may also engage these)

Protein	Name	Similarity
Q4R4P1	—	1.000	Q4R4P1 →
Q9GKX7	—	1.000	Q9GKX7 →
A5A6K9	—	1.000	A5A6K9 →
O02705	—	1.000	O02705 →
P07901	—	1.000	P07901 →
P46633	—	1.000	P46633 →
Q76LV2	—	1.000	Q76LV2 →
O57521	—	1.000	O57521 →
Q6AZV1	—	1.000	Q6AZV1 →
P04809	—	1.000	P04809 →
P30947	—	1.000	P30947 →
P30946	—	1.000	P30946 →
Q76LV1	—	1.000	Q76LV1 →
HSP90AB1	Heat shock protein HSP 90-beta	1.000	landscape →
Q9GKX8	—	1.000	Q9GKX8 →
Q7PT10	—	1.000	Q7PT10 →
Q5R710	—	1.000	Q5R710 →
P40292	—	1.000	P40292 →
P02828	—	1.000	P02828 →
P02829	—	1.000	P02829 →
Q4R4T5	—	1.000	Q4R4T5 →
P11501	—	1.000	P11501 →
O03986	—	1.000	O03986 →
P51818	—	1.000	P51818 →
P24724	—	1.000	P24724 →
Q18688	—	1.000	Q18688 →
P36181	—	1.000	P36181 →
Q8J2M3	—	1.000	Q8J2M3 →
P54651	—	1.000	P54651 →
P41887	—	1.000	P41887 →